NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY – Get Free Report)’s stock price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.00 and traded as high as $0.65. NovaBay Pharmaceuticals shares last traded at $0.62, with a volume of 79,313 shares traded.
NovaBay Pharmaceuticals Stock Performance
The company has a market capitalization of $2.63 million, a price-to-earnings ratio of -0.06 and a beta of 2.82.
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter. The business had revenue of $2.40 million for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 146.20% and a negative net margin of 79.70%. As a group, research analysts expect that NovaBay Pharmaceuticals, Inc. will post -2.54 earnings per share for the current year.
NovaBay Pharmaceuticals Company Profile
NovaBay Pharmaceuticals, Inc develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.
See Also
- Five stocks we like better than NovaBay Pharmaceuticals
- What is an Earnings Surprise?
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- How to invest in marijuana stocks in 7 steps
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.